O
RCUS icon

OrbiMed’s Arcus Biosciences RCUS Stock Holding History

OrbiMed’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-117,000
Closed -$2.23M – 125
2023
Q4 		$2.23M Buy
+117,000
New +$1.87M 0.04% 95
2022
Q4 		– Sell
-303,000
Closed -$7.93K – 130
2022
Q3 		$7.93K Buy
+303,000
New +$8.01M 0.15% 91
2020
Q3 		– Sell
-220,350
Closed -$5.45M – 156
2020
Q2 		$5.45M Buy
+220,350
New +$5.95M 0.08% 118

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

OrbiMed's RCUS Position: Q1 2024 in Review

OrbiMed sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 117,000 shares — an estimated $2.23M sold.

OrbiMed first reported a position in RCUS in Q2 2020 and held it in 3 quarters. The position peaked at $5.45M in Q2 2020. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • OrbiMed reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • OrbiMed sold 117,000 Arcus Biosciences shares in Q1 2024, an estimated $2.23M.
  • OrbiMed first reported a position in Arcus Biosciences in Q2 2020 and held it in 3 quarters.
  • OrbiMed's Arcus Biosciences position peaked at $5.45M in Q2 2020.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.